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INTRODUCTION
Venous thromboembolism (VTE), encompass-
ing deep vein thrombosis (DVT) and pulmo-
nary embolism (PE), and atherothrombosis 
have long been considered to be separate 
entities with distinct pathogenic mechanisms. 
The traditional rationale for this con-
cept has been based on: (1) pathologic data 
showing platelet-rich thrombi in the arteries in contrast to 
‘red clots’ observed in veins; (2) clinical data on a substantial 
efficacy of antiplatelet agents in the prevention of arterial 
thromboembolic events in contrast to negligible benefits 
from these drugs in patients with VTE; (3) experimental data 
demonstrating diffuse inflammatory infiltrates, extracellular 
cholesterol deposits, neovessel formation and calcification 
within advanced atherosclerotic lesions within the arterial 
wall in contrast to minor lesions largely within the endothelial 
layer of the thrombosed veins. 
A key component of this concept is the assumption that 
deranged local processes occurring inside the vessel wall 
account for arterial thrombosis with a minor contribution 
by blood-borne abnormalities, whereas a combination of 
extrinsic factors ranging from venous blood stasis to hyperco-
agulable blood that act on a normal wall of a vein determine 
the occurrence of venous thrombosis.
Experimental data derived from biochemical laboratories, 
cell cultures and animal models has shown however many 
similarities in the pathophysiology of arterial and venous 
thrombosis [1]. Coagulation pathways and their regulation 
are in fact identical in arteries and veins. Blood circulating in 
the two types of vessels is the same in terms of coagulation 
proteins. All kinds of thrombosis are triggered with the same 
major physiological initiator of blood coagulation, i.e. tissue 
factor (TF) [2]. Finally, thrombus composition assessed follow-
ing thrombectomy in patients with ST-segment elevation acute 
myocardial infarction (MI) is frequently hard to differentiate 
from that of thrombi obtained from thrombosed veins, as 
evidenced by the fact that fibrin represents the largest por-
tion of the thrombotic mass in both types of vessels [3, 4]. 
Despite the key role of activated platelets as a driving factor of 
thrombus formation under high shear stress conditions, there is 
convincing evidence for a significant contribution of thrombin 
and blood coagulation proteins in arterial thrombosis, as well 
as for their expression in macrophages and other cells within 
atherosclerotic lesions [5].
Until the beginning of the current century, there was no 
clinical data to support basic science findings indicating that 
thrombus formation in most vessels follows the same pattern 
and once deranged haemostasis tilted toward thrombosis 
results in increased risk of thromboembolic events putting 
in danger both the arterial and venous beds. Within the last 
decade, accumulating evidence has indicated that patients 
following VTE are at risk of MI or ischaemic stroke and vice 
versa. However a lot of experimental and clinical questions 
are to be answered including those as to whether all affected 
patients are indeed prone to develop the other type of throm-
bosis and which diagnostic and therapeutic strategy should 
be adopted in such a clinical setting.
This review summarises the most important clinical and 
experimental data on the association between arterial and 
venous thrombosis.
EPIDEMIOLOGICAL DATA
Does VTE predispose to atherothrombosis?
Prandoni et al. [6] were the first to report that VTE may pre-
dispose to atherosclerosis. In a cross-sectional case-control 
study published in 2003, they showed using carotid ultrasound 
scanning that the prevalence of carotid plaques was higher in 
patients with idiopathic VTE but with no history of sympto-
matic atherosclerosis (47%) than in those with provoked VTE 
(27%) or in age- and sex-matched controls free of thrombosis 
(32%). These differences remained significant after adjusting 
for risk factors for atherosclerosis and thrombophilia. 
Growing evidence indicates that VTE increases the risk of 
subsequent arterial thrombotic events, primarily MI or ischa-




date, Sorensen et al. [10] performed a retrospective analysis 
of nationwide Danish medical databases involving more than 
40,000 patients with VTE and 160,000 controls followed for 
20 years. Comparison of the risks of MI and stroke showed that 
after excluding the patients with arterial hypertension, coronary 
heart disease (CHD), stroke or transient ischaemic attack (TIA), 
subjects with DVT during the first year after the VTE event had 
a relative risk (RR) for MI of 1.60 (95% confidence interval 
[CI] 1.35–1.91) and for stroke of 2.19 (95% CI 1.85–2.60), 
while for patients with PE the corresponding RR values were 
for MI 2.60 (95% Cl 2.14–3.14) and for stroke 2.93 (95% Cl 
2.34–3.66). Increased risks of MI and stroke were also observed 
during the subsequent 20 years of follow-up. Interestingly, these 
relative risks were similar for those with idiopathic VTE and 
those with VTE associated with malignancy, trauma, surgery or 
pregnancy [10]. The increased risk of MI and stroke was high-
est in the first year after diagnosis of VTE despite the standard 
anticoagulant treatment of 3–6 months’ duration [10].
The risk of death from cardiovascular causes was four-fold 
higher in patients with residual thrombus in the veins affected 
by DVT than in those with full recanalisation [11].
In a meta-analysis of six studies on arterial cardiovascular 
events following a VTE episode published in 2010, Becattini et 
al. [12] reported that the risk of arterial cardiovascular events 
was approximately 90% higher in patients with both unpro-
voked (incidence rate ratio [IRR] 1.87; 95% CI 1.32–2.65) and 
provoked VTE (IRR 1.86, 95% CI 1.19–2.89) vs. the controls.
On the other hand, VTE may directly cause arterial 
thrombosis, as evidenced by the well-known phenomenon 
of ‘paradoxical’ embolism through a right-to-left intracardiac 
shunt leading to ischaemic cerebrovascular events [13].
The latest evidence on a possible association between 
VTE and arterial thrombosis came from the prospective cohort 
Tromso study (screening visits in 1994–1995) and the Diet, 
Cancer and Health Study (screening visits 1993–1997) involv-
ing approximately 82,000 subjects aged 24–97 years without 
a previous history of VTE or arterial thrombotic diseases at 
inclusion. In 2013, Lind et al. [14] demonstrated that during 
a median follow-up of 12.2 years, subjects suffering from 
a VTE event had a 35% higher risk of a future arterial event 
(adjusted hazard ratio [HR] 1.35; 95% CI 1.09–1.66). Interest-
ingly, women (but not men) and subjects below 65 years of 
age (but not older) with incident VTE had a 3–4-fold increased 
risk of future MI and ischaemic stroke, with as little as 1% of 
the arterial thrombotic events attributed to VTE [14].
To sum up, several lines of evidence support the view 
that patients who have developed DVT or PE, particularly 
when unprovoked, have a heightened risk of various clinical 
manifestations of atherothrombosis with the largest prevalence 
of MI. However, this concept is exclusively based on findings 
in selective patient cohorts or population-based prospec-
tive registries.
Does atherosclerosis precede VTE?
Several clinical studies have reported that patients with symp-
tomatic atherothrombotic disease, more precisely those who 
experienced MI or ischaemic stroke associated with carotid 
stenosis, are at an increased risk of incident VTE [15]. 
Autopsy studies based on objectively documented 
thrombotic occlusions indicate that also uncommon locations 
of arterial thrombosis other than coronary or carotid artery 
thrombosis can be encountered in patients with a prior his-
tory of VTE. Eliasson et al. [16] reported a higher prevalence 
of VTE in patients with atherothrombotic episodes involving 
the carotid, cranial, visceral, iliac and femoral arteries and the 
aorta, but not of coronary arteries.
Of note, there is no evidence that subclinical athe-
rosclerosis, largely evidenced by increased intima-media 
thickness measured in carotid arteries or by the presence 
of asymptomatic atherosclerotic plaques on ultrasound 
scanning, is associated with an increased risk of VTE. The 
two population-based cohort studies performed in subjects 
aged 45–64 years and in the elderly failed to demonstrate 
any associations of subclinical atherosclerosis with the onset 
of VTE after a mean follow-up of 12.5 years or a lower VTE 
risk during a median follow-up of 11.7 years, respectively 
[17, 18]. 
Atherosclerosis and arterial thromboembolism may 
precede VTE, as reported in a few studies [19]. Symptomatic 
atherosclerosis is observed in about 20% of VTE patients who 
are typically older and are more likely to have immobility, 
prior heart failure, chronic lung disease, cerebrovascular 
disease, and chronic kidney disease compared to the remain-
ing patients; patients with VTE and coexistent atherosclerosis 
receive less frequently thromboprophylaxis when hospitalised 
for causes unrelated to VTE [19].
The best example of such an association is an increased 
risk of VTE, particularly DVT, following MI or stroke, which 
probably results from venous stasis in immobilised patients 
and a transient systemic inflammation and hypercoagulabil-
ity combined with platelet activation following tissue injury.  
To sum up, symptomatic cardiovascular events, particu-
larly MI, can significantly increase the probability of develop-
ing incident VTE, whereas subclinical atherosclerosis is not 
predictive of VTE during a long-term follow-up.
Are risk factors for atherothrombosis  
and VTE identical?
The currently prevalent view assumes that both clinical condi-
tions share a substantial proportion of known risk factors, both 
classic and emerging cardiovascular as well as thrombotic risk 
factors, both genetically determined and transient environ-
mental factors. However, the available evidence indicates that 
some risk factors, predominantly a subset of VTE risk factors, 
are peculiar to either condition.
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Cardiovascular risk factors  
and the risk of VTE
In 2008, Ageno et al. [20] published the largest meta-analysis 
of 21 case-control and cohort studies totalling more than 
63,000 patients that demonstrated the association of car-
diovascular risk factors with VTE. Obesity (odds ratio [OR] 
2.33; 95% CI 1.68–3.24), arterial hypertension (OR 1.51; 
95% CI 1.23–1.85) and diabetes mellitus (OR 1.42; 95% CI 
1.12–1.77) were significantly associated with an increased 
risk of VTE. Surprisingly, no such associations were found for 
current smoking (OR 1.15; 95% CI 0.92–1.44). The same 
holds true for hypercholesterolaemia (OR 1.16, 95% CI, 
0.67–2.02) [20]. 
Some controversy exists around the impact of dyslipi-
daemia on VTE. Compelling evidence indicates that low HDL 
cholesterol is associated with increased risk of VTE [21], which 
has been confirmed in the analysis by Ageno et al. [20]. Hyper-
cholesterolaemia together with arterial hypertension, impaired 
fasting glucose, and abdominal obesity, can independently 
predict idiopathic early-onset VTE [22]. Large cohort studies 
have failed to show any association between lipid profile and 
the risk of VTE during follow-up [20].
Novel or emerging cardiovascular risk factors can also 
predict VTE. For example, it has been shown that patients with 
microalbuminuria are at increased risk of first and recurrent 
VTE [23]. Furthermore, increased C-reactive protein (CRP) in 
circulating blood has been shown to be associated with VTE 
in the general population [24].
To sum up, age, obesity and diabetes have been consist-
ently demonstrated to be associated with higher risk of VTE. 
Less convincing data links VTE with current smoking and 
dyslipidaemia. It should be also highlighted that the significant 
associations between the two types of thromboembolism 
or their risk factors or markers do not necessarily mean 
a cause-effect relationship.
Thrombotic risk factors and atherothrombosis
Genetic VTE risk factors, including factor V Leiden (FVL), 
prothrombin G20210A variant, deficiencies in natural anti-
coagulants, i.e. antithrombin, protein C (PC), protein S (PS), 
positive family history, as well as transient or environmental 
risk factors, including surgery, trauma, prolonged immobility, 
pregnancy, hormone replacement therapy and oral contracep-
tive use, obesity, malignancy, are all consistently associated 
with VTE [25].
Most investigators do not recommend thrombophilia 
screening in patients with arterial thrombosis [26]. The strong-
est evidence suggesting that inherited thrombophilia could 
predispose to arterial thrombosis is based on a meta-analysis 
of 191 studies involving a total of more than 66,000 coronary 
artery disease cases and 90,000 controls [27]. In this study 
published in 2006, Ye et al. [27] reported increased risk of 
MI in carriers of FVL and prothrombin G20210A variant 
(RR 1.17; 95% CI 1.08–1.28 and RR 1.31; 95% CI 1.12–1.52, 
respectively).
Uncommon thrombophilic factors, for example an-
tithrombin deficiency, may heighten the risk of arterial throm-
bosis, particularly in young individuals as shown also in Polish 
patients [28, 29]. A large family cohort study demonstrated 
that hereditary PC (PC antigen < 63% and/or activity < 64%) 
or PS (PS antigen < 68%) deficiency is associated with in-
creased risk of arterial thrombosis, defined as MI, ischaemic 
stroke or TIA, before the age of 55 years, but not in older sub-
jects [30]. In most such cases, arterial thromboembolic events 
occur in subjects with low to moderate atherosclerotic plaque 
burden, indicating a significant impact of a hypercoagulable 
state usually enhanced by a transient factor, for example 
infection. It should be highlighted that in some VTE patients 
with thrombophilia, long-term anticoagulation is effective 
in preventing arterial thromboembolism, thus reducing the 
prevalence of ischaemic stroke if anticoagulation is started 
early after a VTE episode, which hampers the interpretation 
of observational data on the prevalence of MI or stroke in 
thrombophilic subjects. Nevertheless, several experts recom-
mend the determination of thrombophilic factors in stroke 
and/or MI patients below 45–50 years of age, especially in 
the absence of the established cardiovascular risk factors.
There is no doubt that antiphospholipid syndrome (APS), 
a common systemic autoimmune disease characterised by 
the presence of detectable antiphospholipid antibodies, is 
associated with both VTE, which is reported in about 70% 
of APS patients, and arterial thrombosis, mainly cerebrovas-
cular ischaemic events, which occurs in 20% of APS patients 
[31]. Of note, other arterial events are also reported in this 
thrombophilia and the incidence of MI is higher among APS 
patients aged 45 or below than in the general population [32].
Links between acquired transient VTE risk factors and 
arterial thrombosis are less consistent. For example, a meta- 
-ana lysis of 31 randomised controlled trials from 2008 showed 
that hormonal replacement therapy is associated with an 
increase in VTE (OR 2.05; 95% CI 1.44–2.92) and stroke 
(OR 1.32; 95% CI 1.14–1.53) but not in CHD [33].
To sum up, currently inherited thrombophilia has a slight 
or no predictive value of atherothrombosis in the general 
population. Acquired prothrombotic factors, in particular 
APS, increase the risk of MI and stroke.
PATHOPHYSIOLOGICAL BACKGROUND
Mechanisms underlying an association between arterial and 
venous thromboembolism are not fully elucidated. It is known 
that endothelial cell activation and/or damage, combined with 
platelet activation are involved in the initiation of thrombus 
formation in veins and arteries, though their relative contribu-
tion differs with regard to the vessel type. A Virchow’s triad 
can also be perceived as applicable in all types of thrombosis, 




flow and hypercoagulability for VTE and that of endothelial 
damage (or rather that of the intima) for MI. However, cur-
rent evidence challenges this traditional view. Complex fluid 
mechanics in the valve pockets and blood stasis can lead to 
endothelial dysfunction and hypoxia which both may con-
tribute to thrombogenesis [34]. Robust experimental data 
has shown that platelet activation and neutrophil recruitment 
with the formation of neutrophil extracellular traps are also 
involved in the pathogenesis of DVT [34–36]. A role of these 
blood cell-related mechanisms reinforces for example the 
observation that in transgenic mice expressing low levels of 
human TF, flow restriction leads to DVT with fibrin deposition 
in the inferior vena cava, though thrombus growth proceeds at 
a slower rate compared to normal TF expression [36]. On the 
other hand, coagulation proteins are expressed in the arteries 
affected by atherosclerosis, which enhances the inflammatory 
and immunologic processes typical of atherosclerosis [5, 37].
Microparticles, the membrane blebs released into blood 
by activated cells, that are associated with several vascular dis-
eases, in particular CHD, could be another potential mecha-
nism linking atherothrombosis and VTE as for example carriers 
of TF [38]. There have been reports showing an increased 
number of monocyte-derived TF-positive microparticles in 
both first and recurrent DVT compared to normal individuals 
[39]. Moreover, recent evidence indicates that microparticles, 
mainly platelet-derived, contribute to the development of 
damaged vessel wall-induced arterial thrombi by the induc-
tion of increased platelet and fibrin deposition on human 
atherosclerotic arteries [40].
Increased oxidative stress is known to represent a com-
mon denominator in many aspects of cardiovascular diseases 
including atherosclerosis, which appears to be implicated also 
in all types of thrombosis [41]. The augmented generation of 
reactive oxygen species from a number of sources including 
mitochondrial electron transport chain, NADPH oxidase, 
xanthine oxidase, and lipoxygenase/cyclooxygenase has been 
shown in varicose veins [42], suggesting that this mechanism 
might link all types of thrombosis as first suggested more than 
ten years ago [43].
A novel prothrombotic mechanism linking arterial and 
venous thrombosis represents prothrombotic fibrin clot 
phenotype characterised by the formation of more compact 
and highly branched fibrin fibre networks with lower clot 
permeability and prolonged lysis time [44, 45]. This kind of 
clots, with altered fibrin structure and function determined by 
genetic and environmental factors, has been reported in the 
plasma of patients with acute or prior MI, ischaemic stroke, 
as well as those with prior idiopathic VTE [44, 45].
Nowadays, most prothrombotic mechanisms perceived as 
typically venous or arterial could be implicated in thrombosis 
in general, although their relative contribution varies at all 
stages of VTE and atherosclerosis. Much experimental effort 
is needed to clarify complex interactions between several 
potential cellular and plasmatic candidates as drivers of both 
types of thrombosis.
PRACTICAL IMPLICATIONS
The concept of similar pathogenesis of arterial and venous 
thromboembolism has multiple important implications in eve-
ryday practice. Firstly, patients with VTE should be thoroughly 
examined for the presence of not clinically overt atherosclero-
sis in order to identify subjects requiring additional manage-
ment encompassing at least a modification of their risk profile. 
Secondly, some drugs used in cardiovascular disease could be 
effective in reducing the risk of VTE. The best example are 
statins, which produce a number of antithrombotic effects 
largely independent from cholesterol-lowering actions, includ-
ing reduced TF expression, up-regulation of thrombomodulin 
expression on endothelial cells, attenuated platelet activation 
and increased fibrin susceptibility to lysis [46]. In 2009, it 
was demonstrated that rosuvastatin administered to healthy 
subjects with LDL cholesterol < 3.4 mmol/L and slightly 
elevated CRP > 2 mg/L can reduce the risk of symptomatic 
VTE, in particular DVT, by 43% within a two-year follow-up 
[47]. Meta-analysis of available studies, mainly observational, 
confirmed that various statins share the potential to reduce 
the risk of VTE [48]. 
Another example of a medication potentially effective in 
coronary artery disease and VTE appears to be aspirin, a corner-
stone of secondary prevention in atherothrombosis. Recently, 
aspirin has been demonstrated to be effective in the secondary 
prevention of VTE [49]. Despite evidence suggesting the an-
tithrombotic effects of aspirin beyond platelet cyclooxygenase 
inhibition, including acetylation of proteins like fibrinogen 
involved in haemostasis [50], in 2012 the first double-blind 
randomised placebo-controlled WARFASA study by Becattini 
et al. [49] provided a methodologically sound proof of this con-
cept. It was shown that in patients with first-ever unprovoked 
VTE who had completed 6–18 months of oral anticoagulant 
treatment, aspirin given for a median period of 23.9 months 
reduces recurrent VTE compared to a placebo (HR 0.55; 
95% CI 0.33–0.92) [49]. Based on this data, aspirin might be 
considered as a low cost and practical therapeutic option for 
the extension of secondary prophylaxis of unprovoked VTE in 
association with a well established MI or stroke prevention.
Similarly, anticoagulant agents, in particular warfarin, are 
able to reduce atherothrombotic events [51]. Warfarin, a pri-
mary agent used in the secondary prevention of VTE, has been 
shown to decrease the risk of recurrent MI in stable angina 
patients, and it is used now particularly in patients with atrial 
fibrillation and CHD with or without low-dose aspirin [51]. 
Another practical implication of the association between 
various thromboses is the observation that lifestyle modifica-
tions are frequently equally effective in the prevention of VTE 
and atherothrombosis so physicians should encourage patients 
to adhere to them. For example, regular sports activities as 
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well as increased fruit consumption can decrease the risk of 
arterial, as much as of venous, thrombosis [52, 53].
CONCLUSIONS
Despite several unresolved issues, growing clinical evidence 
suggests that thromboembolic events place the affected subject 
in a risk group prone to experience a new episode not only in 
the same kind of vessels. It is likely that the total thrombotic 
risk should be assessed to administer the optimal antithrom-
botic management in patients following either an arterial or 
a venous thromboembolic episode. In the era of personalised 
medicine, most experts recommend that patients following 
MI, ischaemic stroke or any other arterial thrombosis episode 
should be assessed for the risk of VTE and vice versa. In eve-
ryday practice, this view requires for example to consider PE 
always in a patient post MI who complains of dyspnoea, chest 
dyscomfort or refractory cough, or to exclude DVT in a CHD 
patient with calf pain and/or oedema. With the prevalence of 
1 to 1,000 middle-aged people and a 15% death rate in PE, 
VTE is much more common also among patients suffering from 
cardiovascular disease than might have been expected [54].
Large prospective follow-up studies are needed to address 
the pivotal issue as to whether early initiation of anticoagula-
tion in VTE patients confers a lower risk of not only MI, but also 
progression of atherosclerotic vascular disease. Further basic 
science research on the diverse associations between blood 
coagulation and atherosclerosis is needed. Its outcome might 
help optimise cardiovascular risk assessment in VTE subjects.
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